Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - Oncologix Tech Inc.Financial_Report.xls
10-K - FORM 10-K - Oncologix Tech Inc.oncologix8312012.htm
XML - IDEA: XBRL DOCUMENT - Oncologix Tech Inc.R9.htm
XML - IDEA: XBRL DOCUMENT - Oncologix Tech Inc.R5.htm
XML - IDEA: XBRL DOCUMENT - Oncologix Tech Inc.R1.htm
XML - IDEA: XBRL DOCUMENT - Oncologix Tech Inc.R7.htm
XML - IDEA: XBRL DOCUMENT - Oncologix Tech Inc.R8.htm
XML - IDEA: XBRL DOCUMENT - Oncologix Tech Inc.R3.htm
XML - IDEA: XBRL DOCUMENT - Oncologix Tech Inc.R4.htm
XML - IDEA: XBRL DOCUMENT - Oncologix Tech Inc.R6.htm
XML - IDEA: XBRL DOCUMENT - Oncologix Tech Inc.R18.htm
XML - IDEA: XBRL DOCUMENT - Oncologix Tech Inc.R15.htm
XML - IDEA: XBRL DOCUMENT - Oncologix Tech Inc.R20.htm
XML - IDEA: XBRL DOCUMENT - Oncologix Tech Inc.R17.htm
XML - IDEA: XBRL DOCUMENT - Oncologix Tech Inc.R13.htm
XML - IDEA: XBRL DOCUMENT - Oncologix Tech Inc.R19.htm
XML - IDEA: XBRL DOCUMENT - Oncologix Tech Inc.R11.htm
XML - IDEA: XBRL DOCUMENT - Oncologix Tech Inc.R10.htm
XML - IDEA: XBRL DOCUMENT - Oncologix Tech Inc.R16.htm
XML - IDEA: XBRL DOCUMENT - Oncologix Tech Inc.R14.htm
XML - IDEA: XBRL DOCUMENT - Oncologix Tech Inc.R12.htm
EX-21 - SUBSIDIARIES OF ONCOLOGIX TECH, INC. - Oncologix Tech Inc.oncologix8312012exh21.htm
EX-99 - CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - Oncologix Tech Inc.oncologix8312012exh99.htm
EX-31.2 - CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER - Oncologix Tech Inc.oncologix8312012exh312.htm
EX-32.1 - CERTIFICATION - Oncologix Tech Inc.oncologix8312012exh321.htm
EX-31.1 - CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER - Oncologix Tech Inc.oncologix8312012exh311.htm
EX-32.2 - CERTIFICATION - Oncologix Tech Inc.oncologix8312012exh322.htm
v2.4.0.6
Condensed Balance Sheets (USD $)
Aug. 31, 2012
Aug. 31, 2011
Current Assets:    
Cash and cash equivalents $ 1,931 $ 11,067
Prepaid expenses and other current assets 2,993 3,940
Total current assets 4,924 15,007
Property and equipment (net of accumulated depreciation of $8,916 and $21,682) 1,481 364
Total assets 6,405 15,371
Current liabilities:    
Convertible notes payable    150,000
Convertible notes payable - related parties (net of discount of $0 and $0)    235,025
Notes payable - related parties    70,000
Accounts payable and other accrued expenses 142,990 139,801
Accrued interest payable 42,575 32,803
Accrued interest payable - related parties 48,216 34,789
Total current liabilities 233,781 662,418
Long-term liabilities:    
Convertible notes payable - (net of discount of $0 and $0) 125,000   
Convertible notes payable - related parties (net of discount of $0 and $0) 235,025   
Total long-term liabilities 360,025   
Total liabilities 593,806 662,418
Stockholders' Deficit:    
Preferred stock, par value $.001 per share; 10,000,000 shares authorized 129,062 and 129,062 shares issued and outstanding at August 31, 2012 and August 31, 2011, respectively 129 129
Common stock, par value $.001 per share; 200,000,000 shares authorized; 57,563,258 and 50,998,814 shares issued and outstanding at August 31, 2012 and August 31, 2011, respectively 57,563 50,999
Additional paid-in capital 57,697,233 57,358,582
Accumulated deficit prior to reentering development stage (58,004,869) (58,004,869)
Deficit accumulated during the development stage (333,982) (48,427)
Noncontrolling interest (3,475) (3,461)
Total stockholders' deficit (587,401) (647,047)
Total liabilities and stockholders' deficit $ 6,405 $ 15,371